Review of the validated HPLC and LC‐MS/MS methods for determination of drugs used in clinical practice for Alzheimer's disease

Review of the validated HPLC and LC‐MS/MS methods for determination of drugs used in clinical practice for Alzheimer's disease Suresh Ponnayyan Sulochana Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS) Vels University Chennai 600117 India Kuldeep Sharma Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd 2nd Stage, Industrial Suburb, Yeshwanthpur Bangalore 560 022 India Ramesh Mullangi Drug Metabolism and Pharmacokinetics, Jubilant Biosys Ltd 2nd Stage, Industrial Suburb, Yeshwanthpur Bangalore 560 022 India Sathesh Kumar Sukumaran Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS) Vels University Chennai 600117 India ABSTRACT

Alzheimer's disease (AD) is a neurological disorder and is the most frequent type of dementia among elderly people. Donepezil, rivastigmine, galantamine, tacrine and memantine are the US Food and Drug Administration approved oral drugs used in the treatment of AD. Quantitation of these drugs in various biological matrices and monitoring them in long‐term treatment is essential to titer the dose of these drugs and ensure patient compliance. This review provides a comprehensive account of various HPLC and LC‐MS/MS assays, which have been successfully employed to measure the drug levels in various biological matrices arising from preclinical and clinical studies. In addition, this review collates various considerations such as internal standard selection, extraction schemes, matrix effect, selectivity evaluation and optimization of mass spectrometric conditions to enable the development of sound bioanalytical methods for quantitation of Alzheimer's drugs. Overall LC‐MS/MS methods have proven to be the choice of bioanalytical method for the quantification of Alzheimer's drugs in both preclinical and clinical studies. In conclusion, important features of LC‐MS/MS methodology for Alzheimer's drugs include shortened analysis time, increased throughput, selectivity and lower cost of analysis. Copyright © 2014 John Wiley & Sons, Ltd.
02 11 2014 11 2014 1431 1490 10.1002/bmc.3116 http://onlinelibrary.wiley.com/termsAndConditions#vor 10.1002/bmc.3116 https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/bmc.3116 https://onlinelibrary.wiley.com/doi/full/10.1002/bmc.3116 https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fbmc.3116 10.2478/V10007-011-0035-1 10.1016/j.jchromb.2006.10.045 10.2463/mrms.9.95 Journal of Pharmaceutical Research Amini H 115 9 2010 High performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies 10.1016/j.jchromb.2006.10.037 10.4103/0975-1483.90244 10.1002/bmc.1455 10.1016/S0197-4580(98)00052-9 10.1016/j.jchromb.2007.01.003 10.1016/S1474-4422(03)00530-1 10.1016/S0378-4347(00)84380-7 10.1016/S0378-4347(00)82694-8 10.1002/bmc.304 Geriatrics Farlow MR 22 59 2004 NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease 10.1016/S0378-4347(00)80620-9 10.1136/jnnp.66.2.137 10.1002/rcm.2737 10.1016/0378-4347(92)80602-M 10.1016/j.jpba.2009.03.022 10.1016/S0378-4347(98)00183-2 10.1016/S0378-4347(00)84449-7 10.1016/S0378-4347(00)82318-X 10.1007/s10337-012-2292-7 Application to a pharmacokinetic study. Arzneimittelforschung Karthik A 205 58 2008 Fluorimetric determination of rivastigmine in rat plasma by a reverse phase high performance liquid chromatographic method 10.1002/bmc.1709 10.1016/j.clinthera.2011.06.003 10.1016/j.jchromb.2011.10.027 10.1155/2012/101249 10.1016/j.clinthera.2008.04.005 10.1365/s10337-009-1027-x 10.1093/chromsci/42.5.234 10.1016/j.jchromb.2007.03.025 10.1016/0021-9673(94)01005-Y 10.1016/S0378-4347(99)00145-0 10.1177/1091581812447957 10.1016/j.jpba.2005.10.017 10.1093/chromsci/45.2.97 Therapeutic Drug Monitoring Noetzli M 227 33 2011 10.1097/FTD.0b013e31821126cf Simultaneous determination of antidementia drugs in human plasma for therapeutic drug monitoring 10.1016/j.jpba.2012.02.008 10.1365/s10337-009-1231-8 10.1007/s12272-001-1290-6 Journal of Chromatographic Science Park YS 803 50 2012 Quantification of galantamine in human plasma by validated liquid chromatography‐tandem mass spectrometry using glimepiride as an internal standard: application to bioavailability studies in 32 healthy Korean subjects 10.1016/j.aca.2008.09.048 10.1002/bmc.1552 10.5507/bp.2011.036 10.1016/S1570-0232(02)00816-4 10.1093/chrsci/49.10.745 10.1016/j.jchromb.2005.10.031 10.1371/journal.pmed.0040338 10.1002/bmc.1095 10.1016/j.jpba.2007.04.021 SteinerWE PikalovIA WilliamsPT EnglishEAandHilmasCJ.Development of a Novel LC/MS/MS extraction assay for galanthamine in guinea pig plasma and its application to nerve agent countermeasures.Open Access Scient.Rep.2012;1: scientific report 149. 10.1016/S0378-4347(99)00157-7 10.1016/0378-4347(87)80424-3 10.1002/rcm.2758 10.1016/S1570-0232(03)00129-6 10.1111/j.1468-1331.2006.01605.x 10.3389/fnins.2010.00194 10.1002/jssc.201000579 10.1002/rcm.2718 10.1016/S1570-0232(01)00592-X 10.1016/j.jpba.2007.05.028 10.3797/scipharm.1008-17 10.1002/bmc.949 10.1080/03639040600868011